Novel approaches to treatment of leiomyosarcomas

Current Oncology Reports

Volumn 13, Issue 4, 2011, Pages 316-322

  Collins, Ian M ^a   Thomas, David M ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Leiomyosarcoma; p53 mutation; Poly ADP Ribose Polymerase (PARP) inhibitors; Sarcoma

Indexed keywords

AROMATASE INHIBITOR; B RAF KINASE; BEVACIZUMAB; BRCA1 PROTEIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; MYOCARDIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; RIDAFOROLIMUS; SUNITINIB; TRABECTEDIN; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CARCINOGENESIS; CHEMOSENSITIVITY; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG CHOICE; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG TARGETING; HUMAN; LEIOMYOSARCOMA; METASTASIS; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; SURVIVAL RATE; SYSTEMIC THERAPY; UPREGULATION;

EID: 85027917596     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0173-0     Document Type: Article

References (58)

1. Fletcher C, Unni K, Mertens F, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
2. JR Toro LB Travis HJ Wu, et al. 2006 Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases Int J Cancer. 119 12 2922 30 17013893 10.1002/ijc.22239 1:CAS:528:DC%2BD28Xht1yqt7nP (Pubitemid 44846246)
3. CDM Fletcher P Gustafson A Rydholm, et al. 2001 Clinicopathologic Re-Evaluation of 100 Malignant Fibrous Histiocytomas: Prognostic Relevance of Subclassification J Clin Oncol. 19 12 3045 50 11408500 1:STN:280: DC%2BD3MzksFGhsw%3D%3D This important paper suggests that tumors of myogenic origin have a worse outcome than MFH of nonmyogenic origin; and that 20% of MFH may comprise LMS (Pubitemid 32565442)
4. NS Reed C Mangioni H Malmstrom, et al. 2008 Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874) Eur J Cancer. 44 6 808 18 18378136 10.1016/j.ejca.2008.01.019 1:STN:280:DC%2BD1c3kvFWktw%3D%3D
5. Evans H, Shipley J. Leimyosarcoma. In: Fletcher C, Unni K, Mertens F, editors. World Health Organization Classification of Tumors Pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press; 2002. p. 131-4.
6. AP Dei Tos 2003 The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution Virchows Arch. 442 5 421 8 12759750 (Pubitemid 36718308)
7. JM Coindre P Terrier L Guillou, et al. 2001 Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group Cancer. 91 10 1914 26 11346874 10.1002/1097-0142(20010515)91: 10<1914::AID-CNCR1214>3.0.CO;2-3 1:STN:280:DC%2BD3M3ltVKmsA%3D%3D (Pubitemid 32424119)
8. Collaboration SM-a 1997 Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data The Lancet. 350 9092 1647 54 10.1016/S0140-6736(97)08165-8 (Pubitemid 28036824)
9. AW Oosten C Seynaeve PI Schmitz, et al. 2009 Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin Sarcoma. 2009 348910 20066161 10.1155/2009/348910 1:STN:280:DC%2BC3c%2FhvFWmuw%3D%3D
10. M Van Glabbeke AT van Oosterom JW Oosterhuis, et al. 1999 Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens-A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J Clin Oncol. 17 1 150 10458228
11. V Karavasilis BM Seddon S Ashley, et al. 2008 Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients Cancer. 112 7 1585 91 18278813 10.1002/cncr.23332 (Pubitemid 351441172)
12. J Edmonson L Ryan R Blum, et al. 1993 Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas J Clin Oncol. 11 7 1269 75 8315424 1:STN:280:DyaK3szgtFKlsg%3D%3D (Pubitemid 23199129)
13. BM Cantwell J Carmichael S Ghani, et al. 1988 A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma Cancer Chemother Pharmacol. 21 1 49 52 3124971 10.1007/BF00262738 1:STN:280:DyaL1c7js1SjtQ%3D%3D (Pubitemid 18050481)
14. PJ Loehrer Sr GW Sledge Jr C Nicaise, et al. 1989 Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial J Clin Oncol. 7 11 1655 9 2681554 (Pubitemid 19272835)
15. JL Mansi C Fisher E Wiltshaw, et al. 1988 A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma Eur J Cancer Clin Oncol. 24 9 1439 43 3181268 10.1016/0277-5379(88) 90334-3 1:STN:280:DyaL1M%2FjtV2hsA%3D%3D
16. J Schutte HT Mouridsen W Stewart, et al. 1990 Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer. 26 5 558 61 2144740 10.1016/0277-5379(90)90075-5 1:STN:280:DyaK3czotVClsw%3D%3D (Pubitemid 20259327)
17. S Sleijfer M Ouali M van Glabbeke, et al. 2010 Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) Eur J Cancer. 46 1 72 83 19853437 10.1016/j.ejca.2009.09.022 1:CAS:528: DC%2BD1MXhsFGrsbvF
18. ML Hensley R Maki E Venkatraman, et al. 2002 Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial J Clin Oncol. 20 12 2824 31 12065559 10.1200/JCO.2002.11.050 1:CAS:528: DC%2BD38Xlt1KitLg%3D This paper provides evidence of clinical activity of a novel combination chemotherapy in LMS (Pubitemid 34651511)
19. ML Hensley 2010 Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas Curr Opin Oncol. 22 4 356 61 20520541 10.1097/CCO.0b013e32833aafef 1:CAS:528:DC%2BC3cXntF2js70%3D
20. KM Leu LJ Ostruszka D Shewach, et al. 2004 Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma J Clin Oncol. 22 9 1706 12 15117993 10.1200/JCO.2004.08.043 1:CAS:528:DC%2BD2cXpsVWls78%3D (Pubitemid 41079810)
21. JO Bay I Ray-Coquard J Fayette, et al. 2006 Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis Int J Cancer. 119 3 706 11 16496406 10.1002/ijc.21867 1:CAS:528:DC%2BD28Xmtlyjsb4%3D (Pubitemid 43955727)
22. RG Maki JK Wathen SR Patel, et al. 2007 Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002 J Clin Oncol. 25 19 2755 63 17602081 10.1200/JCO.2006.10.4117 1:CAS:528:DC%2BD2sXosValtLY%3D This paper supports the findings of the Hensley paper above [19] (Pubitemid 47123184)
23. SR Patel V Gandhi J Jenkins, et al. 2001 Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation J Clin Oncol. 19 15 3483 9 11481354 1:CAS:528:DC%2BD3MXmtlGhurY%3D (Pubitemid 32730085)
24. M Zewail-Foote LH Hurley 1999 Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove J Med Chem. 42 14 2493 7 10411470 10.1021/jm990241l 1:CAS:528:DyaK1MXjvFGiu7k%3D (Pubitemid 29344290)
25. E Erba D Bergamaschi L Bassano, et al. 2001 Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action Eur J Cancer. 37 1 97 105 11165136 10.1016/S0959-8049(00)00357-9 1:CAS:528:DC%2BD3MXntlOntQ%3D%3D (Pubitemid 32119366)
26. R Garcia-Carbonero JG Supko J Manola, et al. 2004 Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy J Clin Oncol. 22 8 1480 90 15084621 10.1200/JCO.2004.02.098 1:CAS:528:DC%2BD2cXpt1yjurg%3D (Pubitemid 41103631)
27. A Le Cesne JY Blay I Judson, et al. 2005 Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial J Clin Oncol. 23 3 576 84 15659504 10.1200/JCO.2005.01.180 This paper provides evidence that a novel cytotoxic (ecteinascidin) has activity in LMS (Pubitemid 46224235)
28. GD Demetri SP Chawla M von Mehren, et al. 2009 Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol. 27 25 4188 96 19652065 10.1200/JCO.2008.21.0088 1:CAS:528:DC%2BD1MXhtF2jtLrL This paper supports the findings of Le Cesne et al. [27•]
29. J-Y Blay M von Mehren BL Samuels, et al. 2008 Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma Clin Cancer Res. 14 20 6656 62 18927308 10.1158/1078-0432.CCR-08-0336 1:CAS:528: DC%2BD1cXht1Kgur%2FF
30. BA Quinn T Brake X Hua, et al. 2009 Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53 PLoS ONE. 4 12 e8404 20046879 10.1371/journal.pone.0008404
31. AA Ahmed D Etemadmoghadam J Temple, et al. 2010 Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary J Pathol. 221 1 49 56 20229506 10.1002/path.2696 1:CAS:528:DC%2BC3cXntFyjsL4%3D
32. M Krypuy AA Ahmed D Etemadmoghadam, et al. 2007 High resolution melting for mutation scanning of TP53 exons 5-8 BMC Cancer. 7 168 17764544 10.1186/1471-2407-7-168 (Pubitemid 47603601)
33. S Mollerup K Jørgensen G Berge, et al. 2002 Expression of estrogen receptors [alpha] and [beta] in human lung tissue and cell lines Lung Cancer. 37 2 153 9 12140138 10.1016/S0169-5002(02)00039-9 (Pubitemid 34831807)
34. R O'Cearbhaill Q Zhou A Iasonos, et al. 2010 Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors Gynecol Oncol. 116 3 424 9 19932916 10.1016/j.ygyno.2009.10.064
35. DR D'Adamo SE Anderson K Albritton, et al. 2005 Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas J Clin Oncol. 23 28 7135 42 16192597 10.1200/JCO.2005.16.139
36. CF Verschraegen R Quinn I Rabinowitz, et al. 2008 Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS) ASCO Meet Abstr. 26 15 suppl 10534
37. S Sleijfer I Ray-Coquard Z Papai, et al. 2009 Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J Clin Oncol. 27 19 3126 32 19451427 10.1200/JCO.2008.21.3223 1:CAS:528: DC%2BD1MXhtFWitb3P
38. Mahmood ST, Agresta S, Vigil C, et al. Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma. Int J Cancer. 2011. doi: 10.1002/ijc.25843.
39. S George P Merriam RG Maki, et al. 2009 Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas J Clin Oncol. 27 19 3154 60 19451429 10.1200/JCO.2008.20.9890 1:CAS:528: DC%2BD1MXhtFWitb3E
40. RG Maki DR D'Adamo ML Keohan, et al. 2009 Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas Journal of Clinical Oncology. 27 19 3133 40 19451436 10.1200/JCO.2008.20.4495 1:CAS:528:DC%2BD1MXhtFWitb3J
41. JL Ordonez D Osuna DJ Garcia-Dominguez, et al. 2010 The clinical relevance of molecular genetics in soft tissue sarcomas Adv Anat Pathol. 17 3 162 81 20418671 10.1097/PAP.0b013e3181d98cbf
42. S Jain R Xu VG Prieto, et al. 2010 Molecular classification of soft tissue sarcomas and its clinical applications Int J Clin Exp Pathol. 3 4 416 28 20490332 1:CAS:528:DC%2BC3cXmtl2ju7k%3D
43. SP Chawla AW Tolcher AP Staddon, et al. 2007 Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial ASCO Meet Abstr. 25 18 suppl 10076
44. E de Alava 2007 Molecular pathology in sarcomas Clin Transl Oncol. 9 3 130 44 17403624 10.1007/s12094-007-0027-2
45. G Pérot J Derré J-M Coindre, et al. 2009 Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas Cancer Res. 69 6 2269 78 19276386 10.1158/0008-5472.CAN-08-1443
46. R Wang YJ Lu C Fisher, et al. 2001 Characterization of chromosome aberrations associated with soft-tissue leiomyosarcomas by twenty-four-color karyotyping and comparative genomic hybridization analysis Genes Chromosom Cancer. 31 1 54 64 11284036 10.1002/gcc.1118 (Pubitemid 32274133)
47. B Vogelstein D Lane AJ Levine 2000 Surfing the p53 network Nature. 408 6810 307 10 11099028 10.1038/35042675 1:CAS:528:DC%2BD3cXosVemtrY%3D
48. M Ito L Barys T O'Reilly, et al. 2011 Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis Clin Cancer Res. 17 3 416 26 21159888 10.1158/1078-0432.CCR-10-2050 1:CAS:528:DC%2BC3MXhsVers7Y%3D
49. H Calvert A Azzariti 2011 The clinical development of inhibitors of poly(ADP-ribose) polymerase Ann. Oncol. 22 suppl 1 i53 i9 21285153 10.1093/annonc/mdq667
50. PC Fong DS Boss TA Yap, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med. 361 2 123 34 19553641 10.1056/NEJMoa0900212 1:CAS:528:DC%2BD1MXosVKrtrw%3D This important paper supports the hypothesis of synthetic lethality when using PARP inhibitors in the context of tumors with mutations in BRCA1
51. H Farmer N McCabe CJ Lord, et al. 2005 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature. 434 7035 917 21 10.1038/nature03445 15829967 10.1038/nature03445 1:CAS:528:DC%2BD2MXjtFOmsrc%3D (Pubitemid 40559006)
52. A Mangerich A Burkle 2011 How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation Int J Cancer. 128 2 251 65 20853319 10.1002/ijc.25683 1:CAS:528:DC%2BC3cXhsVGrur3J
53. ME Moynahan M Jasin 2010 Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis Nat Rev Mol Cell Biol. 11 3 196 207 20177395 10.1038/nrm2851 1:CAS:528:DC%2BC3cXitlaisbg%3D
54. KV Clark-Knowles MK Senterman O Collins, et al. 2009 Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas PLoS One 4 12 e8534 20046869 10.1371/journal.pone.0008534 This paper provides the first evidence that mutations in Brca1 and p53 co-operate in the development of LMS in the mouse
55. SA Cannistra 2004 Cancer of the ovary N Engl J Med. 351 24 2519 29 15590954 10.1056/NEJMra041842 1:CAS:528:DC%2BD2cXhtVGksbbM (Pubitemid 39603165)
56. H Holstege HM Horlings A Velds, et al. 2010 BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations BMC Cancer. 10 654 21118481 10.1186/1471-2407-10-654 1:CAS:528:DC%2BC3cXhsFCgsrfF
57. P Bouwman A Aly JM Escandell, et al. 2010 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers Nat Struct Mol Biol. 17 6 688 95 20453858 10.1038/nsmb.1831 1:CAS:528:DC%2BC3cXlslyqtLo%3D
58. SF Bunting E Callen N Wong, et al. 2010 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks Cell. 141 2 243 54 20362325 10.1016/j.cell.2010.03.012 1:CAS:528:DC%2BC3cXmtVWnsL0%3D